IDXX vs LNTH stock comparison
IDEXX Laboratories vs. Lantheus · data as of November 13, 2026
IDEXX Laboratories (IDXX) has a market value of about $55.5B, Lantheus (LNTH) about $6.6B. Over their latest twelve months IDEXX Laboratories had revenue of $4.7B and Lantheus $1.6B.
On our five checks IDEXX Laboratories scores higher: 3.4 out of 5 (good) against 2.6 (average).
By area, the stronger company is Lantheus on value; IDEXX Laboratories on future growth; IDEXX Laboratories on track record; IDEXX Laboratories on shareholder returns.
Lantheus is cheaper on earnings (P/E 25.1 vs. 47.5).
IDEXX Laboratories leads on 10 of the compared lines and Lantheus on 11.
Side by side
| IDXX | LNTH | |
|---|---|---|
| Size and price | ||
| Market cap | $55.5B | $6.6B |
| Share price | $704.23 | $101.59 |
| Score | ||
| Overall score (of 5) | 3.4 | 2.6 |
| Value | 0 | 1 |
| Future growth | 4 | 3 |
| Track record | 5 | 2 |
| Financial health | 5 | 5 |
| Shareholder returns | 3 | 2 |
| Valuation | ||
| P/E (TTM) | 47.5 | 25.1 |
| Forward P/E | 44.8 | 16.0 |
| Price / free cash flow | 42.6 | 16.9 |
| Price / sales | 11.9 | 4.3 |
| EV / EBITDA | 33.5 | 17.2 |
| PEG | 3.32 | — |
| DCF value vs. price | −63% | −35% |
| Business | ||
| Revenue | $4.7B | $1.6B |
| Net income | $1.2B | $270M |
| Free cash flow | $1.3B | $393M |
| Net margin | 25.4% | 17.3% |
| Gross margin (5-yr avg.) | 60.2% | 57.3% |
| ROIC (5-yr avg.) | 44.1% | 9.4% |
| Growth | ||
| Revenue growth (1 yr) | 10.4% | 0.5% |
| Revenue growth (5 yrs, per year) | 9.7% | 35.4% |
| EPS growth (5 yrs, per year) | 14.3% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$301M | $59M |
| Dividend yield | None | None |
| Shareholder yield | 2.2% | 4.5% |
| Analysts | ||
| Upside to average target | +2% | +4% |
| Consensus rating | Buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: IDXX TTM to September 30, 2026, LNTH TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, IDEXX Laboratories or Lantheus?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) IDEXX Laboratories scores 3.4 out of 5 and Lantheus 2.6; the table shows where each one is stronger.
Is IDEXX Laboratories cheaper than Lantheus?
On trailing earnings, Lantheus trades at a P/E of 25.1 and IDEXX Laboratories at 47.5, so Lantheus is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, IDEXX Laboratories or Lantheus?
Over five years Lantheus grew revenue about 35.4% a year and IDEXX Laboratories about 9.7% a year.
Full IDEXX Laboratories analysis → Full Lantheus analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.